Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO Wants 14 Years Of Data Exclusivity For Biosimilars; Will Waxman Buy It?

Executive Summary

Biotechnology Industry Organization CEO Jim Greenwood has drawn a line in the sand over follow-on biologics: he will not accept less than 14 years of data exclusivity for innovator products. And he says he has the data to back it up

You may also be interested in...



Follow-On Biologics Under Eshoo’s Bill Not A “Viable Business,” Sandoz Says

No pharmaceutical company will develop follow-on biologics if anything close to the brand-friendly legislation introduced by Rep. Anna Eshoo, D-Calif., to create a regulatory pathway is passed by Congress, Sandoz Biopharmaceuticals head Hannes Teissl said

Follow-On Biologics Under Eshoo’s Bill Not A “Viable Business,” Sandoz Says

No pharmaceutical company will develop follow-on biologics if anything close to the brand-friendly legislation introduced by Rep. Anna Eshoo, D-Calif., to create a regulatory pathway is passed by Congress, Sandoz Biopharmaceuticals head Hannes Teissl said

Senate Follow-On Biologics Bill Still Stuck In Evergreen Forest

Despite moving a bill out of committee last session, the Senate is still wrangling over the issue of whether modifications of existing products should get full exclusivity.

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel